Esther K Schmitt Selected Research

NITD 609

1/2022	High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine.
1/2022	Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated Plasmodium falciparum Malaria.
12/2021	Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa.
7/2020	The early preclinical and clinical development of cipargamin (KAE609), a novel antimalarial compound.
9/2010	Spiroindolones, a potent compound class for the treatment of malaria.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Esther K Schmitt Research Topics

Disease

7	Malaria 01/2022 - 07/2010
4	Infections 12/2021 - 06/2012
2	Falciparum Malaria (Plasmodium falciparum Malaria) 01/2022 - 12/2021
1	Fascioliasis 12/2019
1	Inflammation (Inflammations) 07/2017
1	Neoplasms (Cancer) 08/2015

Drug/Important Bio-Agent (IBA)

5	NITD 609IBA 01/2022 - 09/2010
4	Pharmaceutical PreparationsIBA 07/2020 - 06/2012
2	Lumefantrine Drug Combination Artemether (Coartem)FDA Link 01/2022 - 12/2021
2	Antimalarials (Antimalarial Agents)IBA 07/2020 - 06/2012
1	artemisinin (artemisinine)IBA 01/2022
1	TriclabendazoleIBA 12/2019
1	indoleacrylic acidIBA 07/2017
1	Peptide Elongation Factor 1 (EF-1)IBA 08/2015
1	Carbolines (Beta-Carbolines)IBA 07/2010

Therapy/Procedure

1	Therapeutics 01/2022